Protocol No.: D5290C00004

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
Principal Investigator
Polak, Mark
Phase
III
Age Group
Children
Applicable Disease Site
Other
Participating Institution
Health Sciences Center
Contact
Joseph Scattaregia
Clinical Research Coord
Phone: +1 304-293-9512

View on ClinicalTrials.gov